| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/BMC.3397 |
| P698 | PubMed publication ID | 25472760 |
| P2093 | author name string | Xiaohui Chen | |
| Xing Tang | |||
| Yuanyuan Zhang | |||
| Yu Jiang | |||
| Kaishun Bi | |||
| Liqiang Gu | |||
| Zhenzhen Liu | |||
| Ping Ju | |||
| Simin Zhao | |||
| Lunhui Zhang | |||
| P2860 | cites work | An adjacent arginine, and the phosphorylated tyrosine in the c-Met receptor target sequence, dictates the orientation of c-Cbl binding | Q24316997 |
| Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors | Q27650612 | ||
| Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases | Q27657708 | ||
| The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma | Q30494514 | ||
| Nanoparticulate systems for brain delivery of drugs | Q33938252 | ||
| Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates | Q34088416 | ||
| Small molecule c-Met kinase inhibitors: a review of recent patents | Q34094632 | ||
| c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention | Q34422211 | ||
| Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. | Q35203637 | ||
| MET receptor tyrosine kinase as a therapeutic anticancer target | Q37356047 | ||
| Design, synthesis, and structure-activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents | Q39099004 | ||
| Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors | Q39158608 | ||
| Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference | Q39797652 | ||
| N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors | Q43255650 | ||
| Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation | Q44192096 | ||
| A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. | Q54478410 | ||
| A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors. | Q54649963 | ||
| P433 | issue | 7 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 1103-1111 | |
| P577 | publication date | 2014-12-04 | |
| P1433 | published in | Biomedical Chromatography | Q4915104 |
| P1476 | title | Determination of a novel anticancer c-Met inhibitor LS-177 in rat plasma and tissues with a validated UPLC-MS/MS method: application to pharmacokinetics and tissue distribution study | |
| P478 | volume | 29 |
Search more.